论文部分内容阅读
[目的]为肿瘤的临床个体采化用药和耐药逆转措施的选择提供直接依据,进一步指导临床。[方法]就ERCC1在恶性肿瘤中结构与功能的研究进展进行综述。[结果]核苷酸切除修复交叉互补组1(ERCC1)是一种重要的DNA修复基因,研究已经发现该因子与恶性肿瘤的发病相关,而且与肿瘤的多药耐药、治疗疗效的预测以及治疗预后的判定关系密切。因此进一步深入阐释其作用机制,可能为肿瘤的临床个体化用药和耐药逆转措施的选择提供直接的依据,从而可能对恶性肿瘤的临床诊治带来一种全新的思路和模式。[结论]ERCC1基因与恶性肿瘤的发生、治疗、耐药及预后密切相关,有必要深入进行研究。
[Objective] To provide a direct basis for selection of clinical drug-taking and drug-resistant reversal measures in clinical patients and further guide the clinical practice. [Method] The research progress on the structure and function of ERCC1 in malignant tumors is reviewed. [Results] Nucleotide excision repair cross-complementing group 1 (ERCC1) is an important gene for DNA repair. It has been found that this factor is associated with the development of malignant tumors and is related to the multi-drug resistance of tumors and the prediction of therapeutic efficacy. The prognosis of treatment is closely related to the judgment. Therefore, to further elucidate its mechanism of action may provide a direct basis for clinical individualized drug selection and drug resistance reversal measures, which may bring a new idea and mode for the clinical diagnosis and treatment of malignant tumors. [Conclusion] ERCC1 gene is closely related to the occurrence, treatment, drug resistance and prognosis of malignant tumor. It is necessary to study in depth.